GlassScriptPhysician profile
Adrienne G Shaver
NPI 1659595742
$9,290.70
in general payments reported to CMS, 2019-2025
31 companies · $228 in 2025
The $228 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,974 · 2022: $2,165 · 2023: $2,496 · 2024: $2,428 · 2025: $228.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,981 · Education: $171.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,981.04 |
| Education | $171.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,441.10 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $857.62 | 2021-2025 | Xifaxan, Relistor, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $850.40 | 2021-2025 | Entyvio, Gattex |
| Janssen Biotech, INC. | $847.65 | 2021-2025 | Stelara, Tremfya, Simponi |
| Nestle Healthcare Nutrition INC. | $414.82 | 2021-2023 | |
| Gilead Sciences, INC. | $367.11 | 2021-2025 | |
| Pfizer INC. | $264.87 | 2021-2024 | |
| Regeneron Healthcare Solutions, INC. | $222.87 | 2023-2025 | Dupixent |
| Intercept Pharmaceuticals, INC. | $196.81 | 2021-2024 | Ocaliva |
| Redhill Biopharma INC. | $195.72 | 2021-2024 | Talicia |
| Celgene Corporation | $184.15 | 2021-2024 | Zeposia |
| Merck Sharp & Dohme LLC | $131.36 | 2021-2023 | Dificid |
| Qol Medical, LLC | $130.39 | 2021-2023 | Sucraid |
| Genzyme Corporation | $129.85 | 2022-2024 | |
| Ardelyx, INC. | $128.46 | 2022-2024 | Ibsrela |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $117.97 | 2021-2022 | |
| Braintree Laboratories, INC. | $111.99 | 2021-2023 | Suflave |
| Boehringer Ingelheim Pharmaceuticals, INC. | $106.79 | 2023-2024 | Cyltezo |
| Fresenius Kabi USA, LLC | $104.45 | 2023 | Idacio |
| Celltrion USA INC. | $99.16 | 2024-2025 | Zymfentra, Vegzelma |
| Organon LLC | $84.32 | 2021-2023 | Renflexis, Hadlima |
| Aimmune Therapeutics, INC. | $72.80 | 2024 | |
| Phathom Pharmaceuticals, INC. | $56.03 | 2024 | Voquezna |
| Lilly USA, LLC | $52.46 | 2024 | Omvoh |
| Exeltis, USA INC. | $29.41 | 2024 | Slynd |
| Mylan Institutional INC. | $20.48 | 2023 | Hulio |
| Biocon Biologics INC | $14.44 | 2025 | Yesintek |
| Novo Nordisk INC | $14.40 | 2023 | Wegovy |
| Amgen INC. | $14.34 | 2023 | Avsola, Amjevita |
| Daiichi Sankyo INC. | $14.33 | 2022 | |
| Phadia US INC. | $14.15 | 2024 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adrienne Shaver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.